CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that Judith C. Pelham was elected to its Board of Directors at the Company’s annual meeting on February 10, 2011. She replaces Daniel M. Mulvena who retired after serving on the board since 1998.
Ms. Pelham is President Emeritus of Trinity Health in Novi, Michigan, a national system of healthcare facilities and the third largest Catholic healthcare provider in the U.S. She previously served as President and CEO of Trinity Health from 2000 to 2004, and earlier held executive-level positions at a number of other healthcare systems as well as Brigham and Women's Hospital in Boston. A graduate of Smith College and a recipient of an MPA degree from Harvard University, Pelham presently serves on the Board of Directors of Amgen, Inc. and is on the Board of Trustees of Smith College.
“Judith’s extensive background in healthcare, coupled with her thorough understanding of the nation’s healthcare systems and patient populations, positions her well to make significant contributions to ZOLL’s mission of advancing resuscitation care,” said Benson F. Smith, Chairman. “Her firsthand insight will be a valuable asset in driving the future growth of ZOLL.”
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on February 9, 2011. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.